- Home
- HLIO vs KNSA Comparison
HLIO vs KNSA Comparison
Compare HLIO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLIO
- KNSA
- Stock Information
- Founded
- HLIO 1970
- KNSA 2015
- Country
- HLIO United States
- KNSA United Kingdom
- Employees
- HLIO N/A
- KNSA N/A
- Industry
- HLIO Metal Fabrications
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- HLIO Industrials
- KNSA Health Care
- Exchange
- HLIO Nasdaq
- KNSA Nasdaq
- Market Cap
- HLIO 1.4B
- KNSA 1.5B
- IPO Year
- HLIO N/A
- KNSA 2018
- Fundamental
- Price
- HLIO $26.42
- KNSA $20.21
- Analyst Decision
- HLIO Buy
- KNSA Strong Buy
- Analyst Count
- HLIO 2
- KNSA 6
- Target Price
- HLIO $35.00
- KNSA $37.17
- AVG Volume (30 Days)
- HLIO 315.4K
- KNSA 638.0K
- Earning Date
- HLIO 05-07-2025
- KNSA 04-29-2025
- Dividend Yield
- HLIO 1.36%
- KNSA N/A
- EPS Growth
- HLIO 2.65
- KNSA N/A
- EPS
- HLIO 1.17
- KNSA N/A
- Revenue
- HLIO $805,900,000.00
- KNSA $423,239,000.00
- Revenue This Year
- HLIO $0.84
- KNSA $37.21
- Revenue Next Year
- HLIO $5.98
- KNSA $2.58
- P/E Ratio
- HLIO $22.58
- KNSA N/A
- Revenue Growth
- HLIO N/A
- KNSA 56.60
- 52 Week Low
- HLIO $24.76
- KNSA $16.56
- 52 Week High
- HLIO $57.29
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- HLIO 31.04
- KNSA 44.56
- Support Level
- HLIO $25.47
- KNSA $18.26
- Resistance Level
- HLIO $27.53
- KNSA $21.24
- Average True Range (ATR)
- HLIO 1.77
- KNSA 1.12
- MACD
- HLIO 0.02
- KNSA -0.12
- Stochastic Oscillator
- HLIO 22.07
- KNSA 44.43
About HLIO Helios Technologies Inc.
Helios Technologies Inc is a industrial technology company that develops, manufactures, and markets solutions for the hydraulics and electronics markets. It operates under two business segments: Hydraulics and Electronics. The Hydraulics segment designs and manufactures hydraulic cartridge valves, hydraulic quick release couplings as well as engineers complete hydraulic systems. The Electronics segment designs and manufactures customized electronic controls systems and displays for a variety of end markets including industrial and mobile, recreational and health and wellness.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.